Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. S...
FDA Drug Recall #D-0650-2021 — Class II — June 9, 2021
Recall Summary
| Recall Number | D-0650-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 9, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Genentech Inc |
| Location | South San Francisco, CA |
| Product Type | Drugs |
| Quantity | 88,620 prefilled syringes |
Product Description
Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Syringe. Product of France, Manufactured by: Genentech, Inc. A Member of the Roche Group, South San Francisco, CA 9480-4990. NDC: 50242-215-01
Reason for Recall
Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.
Distribution Pattern
Product was distributed nationwide
Lot / Code Information
Lot No.: 3352758, Exp. Date Aug 2021; Lot No.: 3352759, Exp. Date Aug 2021
Other Recalls from Genentech Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0025-2023 | Class III | Susvimo (ranibizumab injection), 100mg/mL, sold... | Oct 18, 2022 |
| D-0357-2021 | Class III | Evrysdi (risdiplam) for oral solution, 60 mg/80... | Apr 20, 2021 |
| D-087-2013 | Class II | Nutropin AQ NuSpin 20 (somatropin (rDNA origin)... | Sep 20, 2012 |
| D-088-2013 | Class II | Nutropin AQ NuSpin 10 (somatropin (rDNA origin)... | Sep 20, 2012 |
| D-135-2013 | Class I | Trastuzumab Kit containing 1 vial Trastuzumab (... | Jul 30, 2012 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.